< LEADERBOARD/s/butyrateGut & probiotics

Butyrate

Also sold as: Sodium butyrate · Butyric acid · Tributyrin

A short-chain fatty acid produced by microbial fiber fermentation and sold as salts or tributyrin. Oral supplement evidence is much narrower than the established biological role of endogenous butyrate.

Focus

COMMUNITY_STACK_RATINGlive · n=0

Community

Not enough ratings yet: 0 of 10

Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.

+ Rate your experience (30 sec, anonymous)

NERD_PROTOCOL // EVIDENCE_MATRIXper goal

Research

FocusNo established evidence

Focus: No focus-enhancement RCT is supplied. Depression associations and gut-brain mechanisms cannot establish cognitive efficacy; no negative focus RCT is implied.

REALITY CHECK // Butyrate is not a proven SIBO or depression treatment. Oral IBS findings are small and often concern mixtures, while better-documented enema studies do not show consistent UC benefit. Preclinical and biomarker effects should not be presented as clinical cures.

Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.

Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.

CHECK_YOUR_BOTTLE.EXEruns in your browser · nothing is sent or stored

Check your bottle

Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.

Enter the amount from your label to see the result.

How it was studied

01 // STUDIED_DOSE_RANGE

Preparation-specific research

The pediatric IBD trial used150 mg sodium butyrate twice daily for12 weeks and was clinically null. A46-adult proof-of-concept trial used1875 mg/day for12 weeks. Pediatric obesity research used20 mg/kg/day for6 months under supervision; no pediatric self-dosing protocol is implied.

02 // TIMING_&_MATRIX

Matrix and timing

Match the salt, active mass and coating; meal timing has no established universal clinical advantage.

03 // EVALUATION_WINDOW

Trial observation window

Human metabolic trials6–12 weeks; supervised pediatric obesity trial6 months. Acute barrier changes are a different endpoint.

04 // SAFETY_&_QUALITY_GATE

Safety and quality

No established UL. Sodium exposure, coingredients and unexplained persistent GI symptoms need review.

UPPER LIMIT // No EFSA/NIH tolerable upper intake level is established. Research around2 g/day and pediatric weight-based trials are not universal safety ceilings; long-term safety is incompletely characterized.

NERD'S NOTENerd Protocols · a clinical and sports dietitian based in the EU

Summary

IBS findings are preliminary and often confounded by probiotics/prebiotics. A review of8 enema RCTs in227 UC patients did not support clinical use, and a72-patient pediatric oral IBD trial was null. Small metabolic/weight studies are promising but insufficient for a general gut or metabolic cure.

Mechanism

Butyrate fuels colonocytes and influences barrier signaling and histone deacetylases. Endogenous fermentation evidence does not prove that an oral supplement adds benefit beyond adequate fiber; gut use and first-pass metabolism limit systemic exposure.

Typical studied dose

Upper limit

No EFSA/NIH tolerable upper intake level is established. Research around2 g/day and pediatric weight-based trials are not universal safety ceilings; long-term safety is incompletely characterized.

POPULAR_STACKScombos with n ≥ 5

Popular stacks with Butyrate

Not enough stack data yet. A combination with Butyrate appears here once 5 people rate the same set.

> Rate my stack

Forms and label traps

Forms compared
Form on label	Active content	Studied range / day	Absorption & GI tolerance	Verdict
Sodium butyrate Best for: Identify the exact salt mass in the adult proof-of-concept context.	Extract weight · ~100% marker	1875–1875 mg	Rapid upper-GI uptake and metabolism can limit colonic delivery. Strong odor; higher amounts may cause gas or abdominal discomfort.	Studied standard [FORM // TRIAL_CONTEXT] 1875 mg/day is one12-week trial amount, not a general target;100% here means declared sodium-butyrate ingredient mass, not elemental butyrate or sodium. PMID 41880673
Microencapsulated sodium butyrate Best for: Match capsule coating, active salt content and indication.	Extract weight · ~100% marker	300–300 mg	Coating modifies release and masks odor; superior clinical outcomes are not established. Often tolerated; the pediatric IBD trial reported no adverse events.	Good option [FORM // TRIAL_CONTEXT] 300 mg/day belongs to a supervised pediatric IBD trial with no added clinical benefit, not an effective adult IBS dose. PMID 36014789 PMID 32476236
Tributyrin precursor Best for: Sodium-free precursor comparison.	Unstandardized: active content unknown	no comparable trial range	Release rationale includes in vitro digestion and animal colitis research. Digestive tolerance varies; stop for persistent symptoms.	Caution [FORM // NO_VALIDATED_RANGE] No verified human dose interval or head-to-head clinical superiority is supplied. Do not equate precursor mass with delivered colonic butyrate. PMID 28485486 PMID 40695562
Calcium/magnesium butyrate salts Best for: Compare the exact preparation and declared ingredient mass.	Unstandardized: active content unknown	no comparable trial range	No reliable human head-to-head superiority established. Digestive tolerance varies; stop for persistent symptoms.	Caution [FORM // NO_VALIDATED_RANGE] No human head-to-head advantage or verified active fraction supplied. Mineral content must come from the actual label.

Common label traps

TRAP_01 // CURES SIBO
No SIBO-treatment trial is indexed in this dossier; absence of evidence is not a negative RCT.
TRAP_02 // COATING OR TRIBUTYRIN GUARANTEES SUPERIOR RESULTS
Delivery rationale is not a demonstrated clinical head-to-head benefit.
TRAP_03 // GUT-BRAIN MECHANISM MEANS ANTIDEPRESSANT
SCFA associations may reflect reverse causation; no human oral-butyrate depression-treatment RCT is supplied.

Other outcomes studied

Outside the five leaderboard goals. Same evidence levels as above.

ULCERATIVE COLITIS ENEMAS Limited · no benefit
Systematic review:8 RCTs,227 patients; only one showed a disease-activity difference, with no consistent endoscopic/histologic benefit. Gene-expression shifts are not remission.
PMID 33352566 PMID 26607831
PEDIATRIC IBD Limited · no benefit
72 patients aged6–18 received150 mg twice daily for12 weeks: no remission or activity advantage (p=0.37 and0.31). Microbiome changes in another study did not establish clinical benefit.
PMID 36014789 PMID 32476236
IBS SYMPTOMS Limited · benefit
Mixture RCTs and an open/cohort study suggest symptom relief; a colonoscopy model demonstrates an acute permeability effect rather than durable cure.
PMID 39797089 PMID 35371361 PMID 40810534 PMID 40575487
METABOLISM / WEIGHT Limited · benefit
A46-adult12-week study at1875 mg/day reported weight change in participants without diabetes of-7.0±3.0 versus-3.2±1.6 kg (p=0.001); T2D triglycerides changed-0.36 versus+0.08 mmol/L (p=0.012), with+9% time in tight range. These small proof-of-concept findings require replication.
PMID 41880673
PEDIATRIC OBESITY Limited · benefit
A6-month20 mg/kg/day trial favored BMI-SDS improvement; two published corrections mean the exact effect magnitude needs checking. No pediatric protocol is inferred.
PMID 36469320
LIVER DISEASE Limited · benefit
Human findings are preliminary and subgroup-based; the positive NAFLD meta-analysis is preclinical, not human efficacy evidence.
PMID 40565024 PMID 40228267 PMID 35612373
GLYCEMIA IN ANIMALS Limited · no benefit
Mouse insulin-sensitivity benefit conflicts with worsened glucose/lipid regulation in high-fat-fed rats; neither proves human effects.
PMID 19366864 PMID 36606023
DEPRESSION / GUT-BRAIN AXIS No established evidence
Observational SCFA/depression relationships and mechanistic reviews do not establish that oral butyrate treats depression.
PMID 41429215 PMID 40761299 PMID 41865792 PMID 30544489 PMID 27346602
SIBO No established evidence
No supporting treatment trial supplied; the popular cure claim is unestablished.

Reader questions

Is sodium or calcium/magnesium butyrate better?

The minerals are counterions. Consider actual mineral exposure and release system; no reliable clinical head-to-head superiority is supplied.

Do gas and insomnia mean I should push through?

No. Gas is a reported tolerability issue and insomnia reports are anecdotal, not a known required adaptation. Stop for marked or persistent symptoms and review coingredients.

Is tributyrin worth a premium?

Its delivery rationale has in vitro/preclinical support, but this dossier cannot establish superior human outcomes or cost-effectiveness.

Can I use it for a toddler with suspected SIBO?

No home protocol follows from these data. Persistent symptoms in a child require pediatric assessment; supervised IBD/obesity trials do not establish SIBO efficacy.

Stack interactions

Caution Glucose-lowering drugs [CAUTION // CLINICAL_CONTEXT]
A42-patient6-week T2D study had nonsignificant between-group glycemic findings; monitor clinically if adding a supplement, without assuming a reliable drug-like effect.
PMID 35623879 PMID 41880673
Caution Antihypertensives [CAUTION // CLINICAL_CONTEXT]
Within-group BP falls in a small T2D study do not establish a placebo-adjusted antihypertensive action; any additivity remains theoretical.
PMID 35623879
Caution FOS, inulin, PHGG and probiotics [CAUTION // CLINICAL_CONTEXT]
Combination IBS studies cannot separate butyrate from coingredients. Fermentable fiber can increase gas or bloating in fermentation-sensitive people.
PMID 39797089

Red flags: interactions and who should avoid it

Interactions

Possible glucose/BP additivity is theoretical and based on small inconsistent trials. Probiotics and fermentable fibers often accompany butyrate, obscuring its independent benefit; fibers can aggravate gas in susceptible patients.

Avoid or ask a doctor first if

Pregnancy/breastfeeding safety at supplemental doses is unestablished. Pediatric trials were supervised. Persistent pain, severe digestive symptoms or marked insomnia warrant stopping and assessment; sodium-containing forms matter when sodium restriction is required.

Sources (PubMed, 16)

The Effect of Sodium Butyrate Enemas Compared with Placebo on Disease Activity, Endoscopic Scores, and Histological and Inflammatory Parameters in Inflammatory Bowel Diseases: A Systematic Review of Randomised Controlled Trials.
PMID 33352566 · 2021 · systematic review / meta-analysis
Systematic review does not support butyrate enemas for UC clinical outcomes.
Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases-Randomized Placebo-Controlled Multicenter Trial.
PMID 36014789 · 2022 · randomized controlled trial
Null multicenter pediatric IBD trial at150 mg twice daily.
Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease.
PMID 32476236 · 2020 · randomized controlled trial
Microbiota changes do not establish clinical remission.
Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome-A Randomized, Double-Blind, Placebo-Controlled Study.
PMID 39797089 · 2024 · randomized controlled trial
IBS mixture RCT cannot isolate butyrate.
The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome.
PMID 35371361 · 2022 · cohort study
IBS observational/open-label symptom signal.
Acute effects of butyrate on intestinal permeability in patients with irritable bowel syndrome assessed by a novel colonoscopy research model.
PMID 40810534 · 2025 · clinical study / report
Acute intestinal-permeability model, not a durable clinical cure.
The effects of butyrate supplementation on glycemic control, lipid profile, blood pressure, nitric oxide level and glutathione peroxidase activity in type 2 diabetic patients: A randomized triple -blind, placebo-controlled trial.
PMID 35623879 · 2022 · randomized controlled trial
Small T2D study with nonsignificant between-group outcomes.
Targeting weight loss and blood glucose control with oral sodium butyrate in overweight/obese adults with and without type 2 diabetes: A proof-of-concept randomized controlled trial.
PMID 41880673 · 2026 · randomized controlled trial
Small12-week adult proof-of-concept weight/metabolic trial.
Therapeutic Effects of Butyrate on Pediatric Obesity: A Randomized Clinical Trial.
PMID 36469320 · 2022 · randomized controlled trial
Pediatric obesity trial with corrections requiring magnitude review.
Exploring the Potential of Oral Butyrate Supplementation in Metabolic Dysfunction-Associated Steatotic Liver Disease: Subgroup Insights from an Interventional Study.
PMID 40565024 · 2025 · randomized controlled trial
Preliminary human liver-disease subgroup findings.
Efficacy of sodium butyrate in improving nonalcoholic fatty liver disease: A meta-analysis of preclinical studies.
PMID 40228267 · 2025 · systematic review / meta-analysis
Meta-analysis of preclinical liver-disease studies.
Butyrate improves insulin sensitivity and increases energy expenditure in mice.
PMID 19366864 · 2009 · preclinical animal study
Mouse metabolic benefit.
Sodium butyrate aggravates glucose dysregulation and dyslipidemia in high fat-fed Wistar rats.
PMID 36606023 · 2023 · preclinical animal study
Contrasting adverse metabolic findings in rats.
From gut to glee: Is butyrate a promising antidepressant? A systematic review and mechanistic insights.
PMID 41429215 · 2026 · systematic review / meta-analysis
Depression mechanistic review, not human treatment proof.
Circulating short chain fatty acids are associated with depression severity and predict remission from major depressive disorder.
PMID 40761299 · 2025 · case-control study
Observational SCFA and depression association.
In Vitro Digestion and Fermentation of Microencapsulated Tributyrin for the Delivery of Butyrate.
PMID 28485486 · 2017 · in vitro study
In vitro tributyrin delivery rationale.

Community comments

No approved comments yet. Comments are held for moderation.

+ Rate this